导师姓名： 沈坤炜 专业代码： 100210
性别： 男 专业名称： 外科学
培养单位： 附属瑞金医院 三级学科/
专业领域： 普外
导师类型： 博士生导师 专业学位导师： 兼
联系方式： kwshen@medmail.com.cn
邮编： 200025 邮箱地址： kwshen@medmail.com.cn

研究方向 (点击浏览详细信息)
乳腺癌临床与基础转化型研究

社会任职
上海市医学会普外专委会乳腺学长组长
上海交通大学乳腺疾病诊治中心主任
上海市乳腺癌防治专业委员会副主任委员
老年学学会老年肿瘤专业委员会 委员
上海市抗癌协会理事
上海市抗癌协会乳腺癌专业委员会副主任委员

科研项目 项目编号项目名称课题来源起止年月批准经费承担职责
** 乳腺癌微环境中CAF分泌的外泌体递送相关LncRNA介导曲妥珠单抗治疗耐药的研究 国家自然科学基金面上项目 2018-01~2021-12 50万元 课题负责人
DLY201508 紫杉醇±卡铂在三阴性乳腺癌辅助化疗中的临床与疗效预测研究 上海交通大学医学院 2015-12~2017-12 100万元 课题负责人
** 基于乳腺癌数据共享平台的临床诊疗信息分析 上海市科委重点学科“科技创新行动计划” 2015-07~2018-09 50万元 课题负责人
联合靶向抑制CDK4/6和PI3K/Akt/mTOR 通路在ER阳性乳腺癌治疗中的作用 横向课题 2015-06~2018-05 10万元 课题负责人
** 白介素-6激活乳腺癌糖酵解代谢通路与曲妥珠单抗耐药的研究 国家自然科学基金面上项目 2015-01~2018-12 76万元 课题负责人
SHDC** 多基因阵列分析技术在中国Luminal 型乳腺癌规范化个体治疗中的研究 上海申康医院发展中心新兴前沿技术项目 2014-10~2017-09 150万元 课题负责人
** Luminal型乳腺癌个体化内分泌治疗模式的研究 上海市科委重点学科“科技创新行动计划 2014-07~2017-09 300万元 课题负责人
320.6750.12284 中国女性乳腺癌患者PI3K/Akt/mTOR信号传导通路状态检测的研究 吴阶平医学基金会 2012-12~2014-12 20万元 课题负责人
基于中国人群的原代人源乳腺癌移植瘤模型的建立与研究 上海市科委重点课题子课题 2012-11~2014-09 15万元 子课题负责人
Exploring the Effect of Targeting PI3K-Akt-mTOR Pathway in Treatment of Chinese Triple Negative Breast Cancer Patients 横向课题 2012-10~2014-10 20万元 课题负责人
** Lapatinib耐药与乳腺癌上皮间质转化相关信号传导通路关系的研究 国家自然科学基金 2012-01~2015-12 56万元 课题负责人
基础临床交叉团队（乳腺癌） 985三期建设项目 2011-10~2012-10 40万元 子课题负责人
320.6700.09075 循环肿瘤细胞在乳腺癌新辅助化疗中的动态变化及其与疗效的关系 吴阶平医学基金会 2010-02~2011-02 10万元 主要责任人
药物对乳腺癌干细胞靶向治疗作用的研究 上海市科委 2009-07~2012-06 10万元 课题负责人
J50208 乳腺癌的临床研究和基础转化型研究 上海市教委重点学科—肿瘤学 2009-07~2012-12 320万元 子课题负责人
Targeting mTOR and PI3K with RAD001 in breast cancer treatment 横向课题 2009-06~2012-12 30万元 主要责任人
多西他赛联合蒽环类药物和环磷酰胺（TAC）或多西他赛联合环磷酰胺（TC）新辅助治疗三阴性或HER2阳性的乳腺癌临床研究 横向课题 2009-03~2013-06 400万元 课题负责人

学术论文 作者论文标题期刊名出版年卷期页码
Liang Y, Chen X, Tong Y, Zhan W, Zhu Y, Wu J, Huang O, He J, Zhu L, Li Y, Chen W, Shen K （通讯作者） Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era World J Surg Oncol 2019 17(1):37
Huang J, Chen X, Fei X, Huang O, Wu J, Zhu L, He J, Chen W, Li Y, Shen K （通讯作者） Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study Cancer Res Treat. 2019 Epub
Wang W, Chen X, Lin L, Fei X, Garfield DH, Hong J, Gao W, Zhu S, Wu J, Huang O, He J, Li Y, Zhu L, Chen W, Shen K （通讯作者） Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study J Cancer 2018 9(18):3216-3224
Qu F, Chen X, Fei X, Lin L, Gao W, Zong Y, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Shen K （通讯作者） A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score. Chin J Cancer Res. 2018 30(2):222-230.
Wang G, Chen X, Liang Y, Wang W, Fang Y, Shen K （通讯作者） Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen J Breast Cancer 2018 21(3):277-287
Tong Y, Chen X, Fei X, Lin L, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Shen K. （通讯作者） Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease? Eur J Cancer 2018 89:9-18.
Wu J, Fang Y, Lin L, Fei X, Gao W, Zhu S, Zong Y, Chen X, Huang O, He J, Zhu L, Chen W, Li Y, Shen K. （通讯作者） Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. Oncotarget 2017 8(24):38706-38716
Wang G, Chen X, Wang W, Shen K. （通讯作者） A long non-coding RNA signature that predicts pathological complete remission rate sensitively in neoadjuvant treatment of breast cancer Transl Oncol 2017 10(6):988-997.
Lu S, Wu J, Fang Y, Wang W, Zong Y, Chen X, Huang O, He JR, Chen W, Li Y, Shen K （通讯作者）, Zhu L. The impact of surgical excision of the primary tumor in stage IV breast cancer on survival: a meta-analysis Oncotarget 2017 9(14):11816-11823.
Liang Y, Chen X, Zhan W, Garfield DH, Wu J, Huang O, Li Y, Zhu L, Chen W, Shen K. （通讯作者） Can Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node-Negative Disease? Ann Surg Oncol 2017 24(7):1874-1880.
Hong J, Chen X, Huang J, Li C, Zhong L, Chen L, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Wan H, Shen K. （通讯作者） Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study Integr Cancer Ther 2017 16(3):406-413.
Zong Y, Wu J, Shen K. （通讯作者） Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis Oncotarget 2017 7;8(10):17360-17372.
Chen X, Ye G, Zhang C, Li X, Shen K. （通讯作者） Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study. Chin J Cancer Res. 2016 28(6):561-569.
Liu J, Chen X, Ward T, Mao Y, Bockhorn J, Liu X, Wang G, Pegram M, Shen K （通讯作者） Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer Int J Biochem Cell Biol 2016 71:12-23.
Hong J, Mao Y, Chen X, Zhu L, He J, Chen W, Li Y, Lin L, Fei X, Shen K （通讯作者） Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer Tumor Biology 2016 37(3):4135-42
Huang O, Wu D, Zhu L, Li Y, Chen W, Shen K （通讯作者） Concurrent adjuvant radiochemotherapy versus standard chemotherapy followed by radiotherapy in operable breast cancer after breast conserving therapy: A meta-analysis. Journal of Cancer Research and Therapeutics 2016 12(1):84-89
Mao Y, Zhang Y, Qu Q, Zhao M, Lou Y, Liu J, Huang O, Chen X, Wu J, Shen K. （通讯作者） Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells. Mol Biosyst. 2015 11(4):1029-40.
Qu Q, Mao Y, Xiao G, Fei X, Wang J, Zhang Y, Liu J, Cheng G, Chen X, Wang J, Shen K* （通讯作者） USP2 promotes cell migration and invasion in triple negative breast cancer cell lines. Tumour Biol. 2015 36(7):5415-23.
Huang O, Jiang M, Chen XS, Wu JY, Chen WG, Li YF, Shen KW. （通讯作者） Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy. Cell Biochem Biophys 2015 71(2):1181-90.
Chen X, Zhu S, Fei X, Garfield DH, Wu J, Huang O, Li Y, Zhu L, He J, Chen W, Jin X, Shen K. （通讯作者） Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients. BMC Cancer. 2015 5:822
Huang O, Jiang M, Zhang X, Chen X, Wu J, Shen K. （通讯作者） FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis. Tumour Biol. 2014 35(2):1089-94.
Jiang M, Huang O, Xie Z, Wu S, Zhang X, Shen A, Liu H, Chen X, Wu J, Lou Y, Mao Y, Sun K, Hu S, Geng M*, Shen K*. （通讯作者） A novel long non-coding RNA-ARA: Adriamycin Resistance Associated. Biochem Pharmacol 2014 87(2): 254-83.
Chen XS, Yuan Y, Garfield DH, Wu JY, Huang O, Shen KW* （通讯作者） Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. PLoS One. 2014 9(9):e108405 .
Zong Y, Zhu L, Wu J, Chen X, Huang O, Fei X, He J, Chen W, Li Y, Shen KW*. （通讯作者） Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study. PLoS One. 2014 9(8):e95629.
André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014 15(6):580-91
Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K* （通讯作者） The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One. 2014 9(12):e115103.
Wu JY, Chen WG, Chen XS, Huang O, He JR, Zhu L, Li Y, Shen KW* （通讯作者） Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy. Mol Clin Oncol. 2014 2(6):997-1002.
Wu JY, Chen WG, Chen XS, Huang O, He JR, Zhu L, Li Y, Shen KW* （通讯作者）, Chow LW, Loo WT, Chow CY, Tsang W. Outcomes of adjuvant endocrine therapy and hormone receptor status change following neoadjuvant chemotherapy in breast cancer patients. Int J Biol Markers. 2014 29(4):e380-6.
Qu Q, Zong Y, Fei XC, Chen XS, Xu C, Lou GY, Shen KW. （通讯作者） The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer. World J Surg Oncol 2014 12:93.
Huang O, Xie Z, Zhang W, Lou Y, Mao Y, Liu H, Jiang M, Shen K. （通讯作者） A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine?resistant breast cancer cells. Oncol Rep 2014 32(2):627-34.
Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O, Wang J, Yuan F, Sun L, Yu Q, Jin X, Wang J, Shen K. （通讯作者） PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother 2014 63(4):395-406
Zhang X, Mu X, Huang O, Xie Z, Jiang M, Geng M, Shen K. （通讯作者） Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling. PLoS One 2013 8(8):e72053.
Mao Y, Keller ET, Garfield DH, Shen K （通讯作者）, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013 32(1-2):303-15
Qu Q, Mao Y, Fei XC, Shen KW. （通讯作者） The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One 2013 8(12):82650-1
Chen X, Sun L, Mao Y, Zhu S, Wu J, Huang O, Li Y, Chen W, Wang J, Yuan Y, Fei X, Jin X, Shen K. （通讯作者） Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. Mol Cancer Res 2013 11(10):1269-78.
Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H, Geng M, Shen K. （通讯作者） Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules 2013 18(1):701-20.
Chen X, Sun L, Mao Y, Zhu S, Wu J, Huang O, Li Y, Chen W, Wang J, Yuan Y, Fei X, Jin X, Shen K. （通讯作者） Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. BMC Cancer 2013 13:390.
Huang O, Jiang M, Zhang X, Xie Z, Chen X, Wu J, Liu H, Shen K （通讯作者） Grb14 as an independent good prognosis factor for breast cancer patients treated with neoadjuvant chemotherapy. Jpn J Clin Oncol 2013 43(11):1064-72
Chen X, Ye G, Zhang C, Li X, Chen Y, Xie X, Zheng H, Cao Y, Wu K, Ni D, Tang J, Wei Z, Shen K. （通讯作者） Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer. Breast Cancer Res Treat 2013 142(3):549-58
Chen X, Yuan Y, Gu Z, Shen K （通讯作者） Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis Breast Cancer Res Treat 2012 134(3):957-67.
Chen X, Wu J, Lu H, Huang O, Shen K （通讯作者） Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer Cancer Sci 2012 103(2):262-8.
Yuan Y, Chen XS, Liu SY, Shen KW （通讯作者） Accuracy of MRI in Prediction of Pathological Complete Remission in Breast Cancer after Preoperative Therapy: A Meta-analysis AJR 2010 195(1):260-8.
Ma CD, Niu XQ, Luo JM, Shao ZM, Shen KW （通讯作者） Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells Cancer Sci 2010 101(10):2220-6
Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW （通讯作者） Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer Tumori 2010 96(1):103-110.
Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW （通讯作者） Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy Oncology Reports 2010 23(5):1213-20.
Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW （通讯作者） Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Annals of Oncology 2010 21(5):961-967
Huang O, Chen C, Wu J, Chen S, Chen X, Liu G, Hu Z, Lu J, Wu J, Shao Z, Shen Z, Shen K （通讯作者） Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months BMC Cancer 2009 9:375
Huang O, Wang L, Shen K （通讯作者）, Lin H, Hu Z, Liu G, Wu J, Lu J, Shao Z, Han Q, Shen Z. Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat 2008 107(3):379-87.
Ma CD, Chen CM, Chen XS, Liu GY, Di GH, Wu J, Lu JS, Yang WT, Chen JY, Shao ZM, Shen ZZ, Shen KW. （通讯作者） Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer. Anticancer Res 2008 28(5B):3093-7.
Shen KW, Wu J, Lu JS, Han QX, Shen ZZ, Nguyen M, Shao ZM, Barsky SH. Fiberoptic ductoscopy for patients with nipple discharge. Cancer 2000 89(7):1512-9.